The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
===== Transcription ===== Once a virus genome becomes operational in a host cell, it then generates messenger RNA (mRNA) molecules that direct the synthesis of viral proteins. Production of mRNA is initiated by proteins known as transcription factors. Several antivirals are now being designed to block attachment of transcription factors to viral DNA.
== Genomics == Based on a comparative genomic and phylogenomic analysis of 494 complete genomes from the entire Pseudomonas genus, P. syringae does not form a monophyletic species in the strict sense, but a wider evolutionary group (34 genomes in total, organized into 3 subgroups) that includes other species as well. The core proteome of the P. syringae group comprised 2944 proteins, whereas the protein count and GC content of the strains of this group ranged between 4973 and 6026 (average: 5465) and between 58 and 59.3% (average: 58.6%), respectively.
In October 2022, The Gemma Collins Podcast was relaunched, then produced by Acast, who reportedly offered Collins up to "five-times more" than her BBC salary and granted her more "editorial control". The final episode of her podcast aired in February 2024. In December 2022, Collins appeared on the Channel 4 snow-sculpting competition The Greatest Snowman alongside Gareth Malone, Joe Thomas, Melvin Odoom and Yinka Bokinni, in which she created three sculptures; a unicorn, a team built castle alongside Odoom and Thomas, and a sculpture of herself. In March 2023, Collins appeared on the S4C series Mwy Na Daffs a Taffs, in which celebrities visited Wales and immersed themselves in Welsh culture, to disprove the preconceptions and prejudices they may have of the country. After meeting with presenter Miriam Isaac, she is accompanied by Ellis Lloyd Jones, known as drag queen Catrin Feelings, to Treorchy high street, where she visited a local café and sampled Welsh cakes and homemade trifle. She then visited family in Abertillery and discussed the fact that her grandfather used to work on building sites with Tom Jones. The following day she attended the 2022 Ceredigion National Eisteddfod in Tregaron where she was given a tour in a buggy, before observing Welsh folk dancing and the Chairing of the Bard ceremony, however decided to walk out of the latter due to the Gorsedd druids' attitude.
Sources: en.wikipedia.org
=== Natural language processing === Natural language processing (NLP) allows programs to read, write, and communicate in human languages. Specific problems include speech recognition, speech synthesis, machine translation, information extraction, information retrieval, and question answering. Early work, based on Noam Chomsky's generative grammar and semantic networks, had difficulty with word-sense disambiguation unless restricted to small domains called "micro-worlds" (due to the common sense knowledge problem). British linguist and philosopher Margaret Masterman believed it was meaning and not grammar that was the key to understanding languages, and that dictionaries and especially thesauri should be the basis of computational language structure. Modern deep learning techniques for NLP include word embedding (representing words, typically as vectors encoding their meaning), transformers (a deep learning architecture using an attention mechanism), and others. In 2019, generative pre-trained transformer (or "GPT") language models began to generate coherent text. By 2023, these models were able to get human-level scores on the bar exam, SAT (Scholastic Assessment Test), GRE (Graduate Record Examination), and many other real-world applications.
(2026) identify bone fragments and teeth from the Pleistocene strata from the Bianfu Cave (Yunnan, China) as Denisovan remains, while Ruan et al. (2026) study archaeological remains associated with Denisovan fossils from the Bianfu Cave, interpreted as indicative of specialized hunting, expedient production of stone tools and extensive use of unmodified bones by Denisovans. Hublin et al. (2026) report the discovery of new, approximately 773,000-years-old hominin fossils from Grotte à Hominidés at Thomas Quarry I in Casablanca (Morocco), close in age to Homo antecessor but morphologically distinct from members of this species, preserving a combination of primitive and derived traits seen in Eurasian archaic hominins and in Homo sapiens. Evidence from the study of a stratified sequence of lithic assemblages ranging from Acheulian to the Middle Stone Age from the Amanzi Springs archaeological site (South Africa), indicative of emergence of the Middle Stone Age in the studied area around 230,000 years ago, is presented by Blackwood et al. (2026). Evidence of consistent and specialized extraction of hornfels for the production of stone tools between 220,000 and 110,000 years ago is reported from the Jojosi site (South Africa) by Will et al. (2026). Beyene et al. (2026) report the discovery of approximately 100,000-years-old human skeletons and Middle Stone Age artifacts from the Halibee member of the Dawaitoli Formation (Ethiopia), interpreted as preserved in a wooded depositional environment with seasonal flooding. Zimmer et al.
Cauliflower ear is an irreversible condition that occurs when the external portion of the ear is hit and develops a blood clot or other collection of fluid under the perichondrium. This separates the cartilage from the overlying perichondrium that supplies its nutrients, causing it to die and resulting in the formation of fibrous tissue in the overlying skin. As a result, the outer ear becomes permanently swollen and deformed, resembling a cauliflower, hence the name. The condition is common in sport wrestling, professional wrestling, boxing, and kickboxing, in martial arts such as Brazilian jiu-jitsu, judo, sumo, and mixed martial arts, and in full-contact sports such as rugby union and rugby league.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.